The resulting commonalities have led to development of new models and approaches to biological therapies covering the whole spectrum of immune responses. CLASSICAL ANTI-CANCER DRUGS cancer therapy which have found applications in other ...
ISBN-13: 978-3-642-72125-0 e-ISBN-13: 978-3-642-72123-6 DOI: 10.1007/978-3-642-72123-6 ISSN 0080-0015 Library of Congress Cataloging-in-Publication Data Neymark, Niels: Assessing the economic value of anti-cancer therapies / N. Neymark.
Author: Niels Neymark
Publisher: Springer Science & Business Media
With ever increasing demands on the constrained resources available for health care services, no one involved in decision making in health care can continue to ignore the economic costs of the services provided or the relative value for money offered by the available treatments. Economic evaluation has therefore become an important and indispensable tool for medical deci sion making, alongside the well-known methods for clinical eval uation. This is also true for cancer, despite the aura of sanctity often of surrounding this dreaded disease and the apparent willingness the general population to spend large sums in this area and do "everything possible" for the patients. In recent years, articles dealing with assessing the costs and benefits of various cancer treatments have begun to appear in scientific medical and eco nomic journals. This book provides a comprehensive survey and assessment of the current state of the art of economic evaluations and cost ana lyses in cancer. It gives an introduction to the methods available for economic evaluations, before surveying and assessing the available publications. Separate chapters are devoted to the most prevalent cancers, and in each chapter the current clinical prac tice and research problems are summarized in order to provide a background for the economic analyses. At the end, a summary assessment of the literature is provided along with some sugges tions for a future research agenda.
While AGEP has been associated with anticancer therapies (Table 21.4), it is most commonly reported in association with antibiotics, hydroxychloroquine, and calcium channel blockers, namely diltiazem. Table 21.4 • AGEP-Associated Cancer ...
Author: Allireza Alloo
Publisher: Lippincott Williams & Wilkins
Many oncologic therapies used to treat cancer have significant implications for the skin. These dermatologic reactions follow recognizable patterns and are closely related to the type of treatment given.Cutaneous Toxicities from Anti-Cancer Therapies, by Drs. Allireza Alloo and Nicole LeBoeuf, provides comprehensive coverage of cutaneous toxicities caused by the full spectrum of oncologic modes of treatment—specifically cytotoxic chemotherapy, targeted chemotherapy, and immunotherapy. This portable photoguide is a quick bedside handbook for dermatologists, oncologists, primary care providers, emergency room physicians, and other health care professionals who see patients undergoing treatment for cancer.
published: 20 May 2020 doi: 10.3389/fphar.2020.00733 Discovering Anti-Cancer Drugs via Computational Methods Wenqiang and Shuguang ... Recently, the rapid growth of computational tools for drug discovery, including anticancer therapies, ...
published: 11 January 2021 doi: 10.3389/fmolb.2020.597634 External and Internal Stimuli-Responsive Metallic Nanotherapeutics for Enhanced Anticancer Therapy Adityanarayan Mohapatra 1, Saji Uthaman2 and In-Kyu Park 1* 1 Department of ...
Author: Christopher D. GregoryPublish On: 2016-08-24
This chapter further provides a tour de force of the responses of cells to irradiation and their application in anticancer therapies. Extending the theme of apoptosis-inducing anticancer therapy, Klaus-Michael Debatin and his colleagues ...
Author: Christopher D. Gregory
This book discusses properties of apoptosis and other cell death modalities in cancer pathogenesis and treatment. Its nine chapters discuss modulation of anti-tumor inflammatory and immune responses, effects on the tumor microenvironment, to strategies for improving pro-apoptotic therapies, mechanisms and implications for disease pathogenesis, axl and mer receptor tyrosine kinases, immunogenic apoptotic cell death and anti-cancer immunity and cancer cell death-inducing radiotherapy. This book places the onco-biology of apoptosis in clear and objective perspective through an expertly synthesized series of reviews. Apoptosis in Cancer Pathogenesis and Anti-cancer Therapy is a deft and thorough exploration of cutting-edge research in apoptosis and anti-cancer mechanisms from basic biology to oncology. It highlights a rapidly growing field within cancer research and is essential reading for oncologists, biochemists and advanced graduate students alike.
Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. Eur J Cancer. ... Carbon nanotubes as a novel drug delivery system for anticancer therapy: a review. Braz J Pharm Sci.
Author: Loutfy H. Madkour
Publisher: CRC Press
This book presents an overview of the current status of translating the RNAi cancer therapeutics in the clinic, a brief description of the biological barriers in drug delivery, and the roles of imaging in aspects of administration route, systemic circulation, and cellular barriers for the clinical translation of RNAi cancer therapeutics, and with partial content for discussing the safety concerns. It then focuses on imaging-guided delivery of RNAi therapeutics in preclinical development, including the basic principles of different imaging modalities, and their advantages and limitations for biological imaging. With growing number of RNAi therapeutics entering the clinic, various imaging methods will play an important role in facilitating the translation of RNAi cancer therapeutics from bench to bedside. RNAi technique has become a powerful tool for basic research to selectively knock down gene expression in vitro and in vivo. Our scientific and industrial communities have started to develop RNAi therapeutics as the next class of drugs for treating a variety of genetic disorders, such as cancer and other diseases that are particularly hard to address with current treatment strategies. Key Features Provides insight into the current advances and hurdles of RNAi therapeutics. Accelerates RNAi, miRNAs, and siRNA drug development for cancer therapy from bench to bedside. Addresses various modifications and novel delivery strategies for miRNAs, piRNAs and siRNA delivery in anticancer therapeutics. Explores the need for the interaction of hematologists,cell biologists, immunologists, and material scientists in the development of novel cancer therapies. Describes the current status of clinical trials related to miRNA and siRNA-based cancer therapy Presents remaining issues that need to be overcome to establish successful therapies.
These results indicated that the development of small molecule drugs for the treatment of NSCLC is still of great ... and improve the sensitivity of cancer cells to anticancer therapy by interfering with miRNA (Seo et al., 2019; ...
188.8.131.52 Pyrimidine Analogues as Anticancer Agents After it became evident that malignant tissues use uracil comparatively faster than normal tissues, the idea of possible use of pyrimidine analogues in anticancer therapy gained interest ...
Author: Shabir Ahmad Ganai
Publisher: Springer Nature
This book reviews the latest developments in the design, synthesis, and molecular mechanism of action of Histone Deacetylase (HDAC) inhibitors in the context of potential cancer therapy. HDAC inhibitors are emerging as promising anticancer drug molecules that promote growth arrest, differentiation and apoptosis of cancer cells with tumor selective toxicity. The book begins with an overview of various epigenetic modifying enzymes that are involved in cancer transition and progression; before exploring the potential of HDACs in cancer treatment. It provides a classification of HDAC inhibitors based on their structural attributes, and addresses HDAC-induced cytotoxicity.. Lastly, it discusses and assesses the rationale behind therapies that combine HDAC inhibitors with other anticancer agents to treat solid tumors. Given its scope, it offers a valuable resource for all researchers, clinicians, and students working in formulation, drug discovery, oncology, and personalized medicine.
Mol Oncol 10:101–121 Matthews TP, Jones AM, Collins I (2013) Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies. Expert Opin Drug Discov 8:621–640 Maugeri-Sacca M, ...
Author: John Pollard
Over the past decade a complex role for DNA damage response (DDR) in tumorigenesis has emerged. A proficient DDR has been shown to be a primary cause for cellular resistance to the very many DNA damaging drugs, and IR, that are widely used as standard-of-care across multiple cancer types. It has also been shown that defects in this network, predominantly within the ATM mediated signaling pathway, are commonly observed in cancers and may be a primary event during tumorigenesis. Such defects may promote a genomically unstable environment, facilitating the persistence of mutations, any of which may provide a growth or survival advantage to the developing tumor. In addition, these somatic defects provide opportunities to exploit a reliance on remaining repair pathways for survival, a process which has been termed synthetic lethality. As a result of all these observations there has been a great interest in targeting the DDR to provide anti-cancer agents that may have benefit as monotherapy in cancers with high background DNA damage levels or as a means to increase the efficacy of DNA damaging drugs and IR. In this book we will review a series of important topics that are of great interest to a broad range of academic, industrial and clinical researchers, including the basic science of the DDR, its role in tumorigenesis and in dictating response to DNA damaging drugs and IR. Additionally, we will focus on the several proteins that have been targeted in attempts to provide drug candidates, each of which appear to have quite distinct profiles and could represent very different opportunities to provide patient benefit.